CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
This article was originally published in PharmAsia News
Executive Summary
CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY